Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Veracyte Inc (VCYT)

Veracyte Inc (VCYT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,188,161
  • Shares Outstanding, K 71,576
  • Annual Sales, $ 219,510 K
  • Annual Income, $ -75,560 K
  • 60-Month Beta 1.17
  • Price/Sales 5.43
  • Price/Cash Flow N/A
  • Price/Book 1.17
Trade VCYT with:

Options Overview Details

View History
  • Implied Volatility 54.06% ( -0.06%)
  • Historical Volatility 55.67%
  • IV Percentile 2%
  • IV Rank 28.25%
  • IV High 148.96% on 06/13/22
  • IV Low 16.69% on 09/23/22
  • Put/Call Vol Ratio 0.25
  • Today's Volume 15
  • Volume Avg (30-Day) 57
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 3,909
  • Open Int (30-Day) 3,771

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.24
  • Number of Estimates 4
  • High Estimate -0.19
  • Low Estimate -0.29
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -84.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.08 +3.23%
on 09/23/22
21.17 -21.59%
on 08/31/22
-3.83 (-18.75%)
since 08/30/22
3-Month
16.08 +3.23%
on 09/23/22
28.27 -41.28%
on 08/08/22
-3.30 (-16.58%)
since 06/30/22
52-Week
14.85 +11.78%
on 05/12/22
54.13 -69.33%
on 11/04/21
-29.85 (-64.26%)
since 09/30/21

Most Recent Stories

More News
Should Growth Investors Buy This Little-Known Stock?

Due to the downturn in the broader market, this genetic-testing stock has crashed so far this year.

COMP : 2.32 (-0.43%)
VCYT : 16.60 (-0.24%)
New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men

Veracyte, Inc . (Nasdaq: VCYT) announced that data published today in the Journal of the National Cancer Institute demonstrate that the company’s Decipher Prostate Genomic Classifier may help identify...

VCYT : 16.60 (-0.24%)
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access

Veracyte, Inc. (Nasdaq: VCYT) announced today that John Leite, Ph.D., has joined the company as senior vice president and general manager of Pulmonology & Market Access. Dr. Leite’s responsibilities...

VCYT : 16.60 (-0.24%)
New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer

Veracyte, Inc . (Nasdaq: VCYT) announced that new data from a Phase 3 trial of the multi-center, multi-national, randomized STAMPEDE platform protocol confirm the ability of the company’s Decipher Prostate...

VCYT : 16.60 (-0.24%)
New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy

Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting that the Envisia Genomic Classifier (EGC) can help predict which patients with interstitial lung disease (ILD), including idiopathic pulmonary...

VCYT : 16.60 (-0.24%)
Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 20 th...

VCYT : 16.60 (-0.24%)
Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022

Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts showcasing the company’s genomic tests for prostate (Decipher) and breast (Prosigna) cancers will be presented at the European Society...

VCYT : 16.60 (-0.24%)
New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma

Veracyte, Inc. (Nasdaq: VCYT) announced that new data published today in Nature Medicine provide the first evidence that the pre-treatment tumor microenvironment (TME) can impact response to chimeric-antigen-receptor...

VCYT : 16.60 (-0.24%)
3 Cathie Wood Stocks for the Future

Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.

FATE : 22.41 (+0.31%)
VCYT : 16.60 (-0.24%)
ADPT : 7.12 (+3.94%)
Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors

Veracyte, Inc. (Nasdaq: VCYT) today announced the appointment of Eliav Barr, M.D., to its board of directors, effective immediately.

VCYT : 16.60 (-0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also...

See More

Key Turning Points

3rd Resistance Point 18.03
2nd Resistance Point 17.72
1st Resistance Point 17.16
Last Price 16.60
1st Support Level 16.29
2nd Support Level 15.98
3rd Support Level 15.42

See More

52-Week High 54.13
Fibonacci 61.8% 39.13
Fibonacci 50% 34.49
Fibonacci 38.2% 29.85
Last Price 16.60
52-Week Low 14.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar